ALLK: Allakos Inc Price to Sales
Allakos Inc. faces a liquidity shortage threat and a dependence on external financing due to a lack of commercial products. The unpredictability of immune drug trials creates a risk of a price collapse in the event of negative test results. The ratio of cost to sales volume on this GURU.Markets chart shows that the parameter value reaches . The company is currently cutting costs, having completely halted business scaling.
Analytical breakdowns for Allakos Inc. (ALLK)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- company profitability and valuation multiples indicators:
ALLK - Net Income|Expected Net Income Allakos Inc.|ALLK - P/E Multiple|Market Cap to Projected Earnings allakos.com|ALLK - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Allakos Therapeutics|ALLK - Operating profit EBITDA|Net earnings per share for the last 12 months Allakos|ALLK - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months allakos.com|ALLK - Earnings growth in current year|Earnings growth forecast for next year Allakos Inc.
- total revenue and sales volume data:
Fundamental company analysis:ALLK Allakos Inc
The P/S ratio compares the market value of Allakos Inc. (ALLK) to its sales volume, allowing for an assessment of whether the capitalization is fair relative to revenue generation rates. By analyzing the price-to-sales multiple through the lens of antibody development for inflammation therapy, an investor can determine if the potential of the research centers is overvalued, which is critical for ensuring the stability of the invested capital.
Competitors of Allakos Inc.
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|PTGX - P/S Multiple|Immunovant, Inc. (IMVT) - Price-to-Revenue Ratio|KNSA (kiniksa.com) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Grifols|Price-to-Revenue Ratio ADPT|P/S Multiple CLDX|P/S Multiple Aurinia Corp (AUPH)|Price-to-Revenue Ratio BioCryst BCRX|P/S Multiple veratx.com VERA|DNTH - Price-to-Revenue Ratio|Price to Sales Pharvaris NV|AbCellera Biologics Inc (ABCL) - Price-to-Revenue Ratio|TRML - Price-to-Revenue Coefficient|Market Cap to Revenue PGEN|PHAR: Market Capitalization-to-Revenue Ratio|P/S Multiple NKTR|Price-to-Revenue Coefficient Upstream Bio, Inc.|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|IMNM: Market Cap to Revenue Ratio|Gossamer Bio, Inc. - P/S Multiple|kalvista.com (KALV) - Market Cap to Revenue|SEPN (Septerna) - Market Cap to Revenue|PVLA - Price-to-Revenue Coefficient|SVRA (Savara Corp) - P/S Multiple|P/S Multiple Rigel Corp|Price-to-Revenue Ratio AnaptysBio, Inc. (ANAB)|Price-to-Revenue Ratio ATXS (astriatx.com)|Price-to-Revenue Ratio enGene ENGN|RAPT Therapeutics Inc. - Price-to-Revenue Ratio|JBIO - Price-to-Revenue Ratio|ACRS - P/S Multiple|Kyverna Therapeutics (KYTX) - Price-to-Revenue Ratio|Price-to-Sales Ratio TLSA (tizianalifesciences.com)|CABA (Cabaletta Bio) - P/S Multiple|VTYX: Market Capitalization-to-Revenue Ratio|P/S Multiple THTX|P/S Multiple Avalo Therapeutics Inc (AVTX)|Price-to-Revenue Ratio Eledon Pharmaceuticals ELDN|Market Capitalization-to-Revenue Ratio AGEN|CLYM - Price-to-Revenue Ratio|Zura Bio Ltd (ZURA) - Market Cap to Revenue|ATYR: P/S Multiple|Adagene Inc. (ADAG) - P/S Multiple|Market Cap to Revenue IMA|STTK: Market Capitalization-to-Revenue Ratio|P/S Multiple EQ|Price-to-Revenue Coefficient connectbiopharm.com|Price-to-Revenue Ratio Immunic IMUX|ATRA - Market Cap to Revenue|IFRX - Price-to-Revenue Ratio|x4pharma.com (XFOR) - Market Cap to Revenue|ACET (adicetbio.com) - Market Cap to Revenue|Celularity (CELU) - P/S Multiple|Price-to-Revenue Ratio INmune Bio Corp|Market Cap to Revenue Ratio BRNS (Barinthus Biotherapeutics Corp)|P/S Multiple KZR|SABS - Price to Sales|P/S Multiple AKTX (Akari Therapeutics Plc)|P/S Multiple Enlivex Therapeutics Ltd ENLV|QTTB - Price-to-Revenue Ratio|GOVX: Price-to-Revenue Ratio|Edesa Biotech, Inc. (EDSA) - Price-to-Revenue Ratio|IBIO (ibioinc.com) - Price-to-Revenue Ratio|CARM (Carisma Therapeutics Inc) - P/S Multiple|P/S Multiple XTL Biopharmaceuticals Ltd|Price-to-Revenue Ratio Bolt Biotherapeutics (BOLT)|P/S Multiple hcwbiologics.com (HCWB)|Price-to-Revenue Ratio Aptevo Therapeutics Inc. APVO|AIM ImmunoTech, Inc. (AIM) - Price to Sales|ADTX - Price-to-Revenue Ratio|Price-to-Revenue Coefficient GRI Bio Inc GRI|XRTX (XORTX) - Market Cap to Revenue|Vyome Therapeutics - Market Capitalization-to-Revenue Ratio|REVB (Revelation Biosciences) - P/S Multiple|indaptusrx.com (INDP) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|calcimedica.com - Market Cap to Revenue Ratio|P/S Multiple AFMD (Affimed N.V.)|HOOK - Market Cap to Revenue|IGMS: Market Cap to Revenue|Price-to-Revenue Coefficient iteostherapeutics.com ITOS|OCEA: P/S Multiple|TC BioPharm (Holdings) Plc (TCBP) - P/S Multiple|Price-to-Revenue Ratio Third Harmonic Bio, Inc
